Table 3.
A summary of the MOF-NZs used in the treatment of cancer
| Materials | Tumor model | Treatment technique | Inhibition | Ref |
|---|---|---|---|---|
| O2-evolving | ||||
| UiO-66-NH2/PB-DOX | Breast cancer | PTT/CHT | 80% < | [139] |
| Zr6C72H45N6O12-Mn1.5 | Liver cancer | SDT/IMT | 89% < | [140] |
| TPP-DNB@ZIF-8 | Breast cancer | PDT | 85% < | [141] |
| TPZ@porphyrinic MOFs | Colon cancer | PDT/CHT/IMT | 87% < | [142] |
| AuNPs-Fe@GOx | Lung cancer | PTT | 80% < | [54] |
| Toxic agents | ||||
| HA@MIL-100(Fe)/D-Arginine | Osteosarcoma | RT | 90% < | [143] |
| Cu-MOFs/Ce6 | Breast cancer | CDT/SDT | 75% < | [144] |
| PCN-224-Pt | Liver cancer | PDT | 78% < | [145] |
| Zr-Fc MOFs | Breast cancer | PTT/CDP | 90% < | [146] |
| Starvation | ||||
| Banoxantrone/GOx@ZIF-8@Cell membrane | Liver cancer | CHT | 85% < | [147] |
| Carbone-oxide framework@GOx-CAT | Breast cancer | PDT | 80% < | [148] |
| MnO2 nanosheets-GOx | Melanoma cancer | PDT | 90% < | [149] |
| GOx@Pd@ZIF-8 | Lung cancer | CDT | 50% < | [150] |
| Fe-hemoporfirin frameworks–GOx/CAT | Breast cancer | SDT | 75% < | [151] |
| GSH depletion | ||||
| MnFe2O4@Zr-TCPP-PEG | Breast cancer | PDT | 75% < | [152] |
| Fe·Cu-SS-PEG@DOX MOFs | Breast cancer | CDT/PTT/CHT | 70% < | [153] |
| PCN-224(Cu)-GOD@MnO2 | Cervical cancer | CDT | 90% < | [154] |
| mFe(SS)/GSH MOFs | Breast cancer | CHT/IMT | 75% < | [155] |
| Cu‐Pd@MIL‐101 | Solid tumor | CDT | 70% < | [156] |
| Catalytic cascades enhanced | ||||
| P@Pt@P–Au–FA | Breast cancer | PDT: GOx + CAT | 75% < | [50] |
| GOx@ZIF@Metal polyphenol | Breast cancer | CDT: GOx + CAT + Fenton | 85% < | [157] |
| Mn-Zr(MOFs) nano-clusters | Liver cancer | MDT: GOx + CAT | 85% < | [158] |
| siRNA/Zr-Fe–P MOFs | Breast cancer | PTT/PDT: GOx + CAT | 80% < | [159] |